| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PHRS.2003.11.011 |
| P698 | PubMed publication ID | 15082034 |
| P2093 | author name string | Ismail Temel | |
| Haluk Savli | |||
| Akif Kaygusuz | |||
| Ayhan Boluk | |||
| Handan Işin Ozişik | |||
| Mehmet Guzelipek | |||
| P2860 | cites work | Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy | Q43705798 |
| P433 | issue | 1 | |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 93-97 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Pharmacological Research | Q15724622 |
| P1476 | title | The effect of valproate on bone mineral density in adult epileptic patients | |
| P478 | volume | 50 |
| Q43291757 | A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. |
| Q36605584 | A review of the effect of anticonvulsant medications on bone mineral density and fracture risk |
| Q34580116 | Anti-epileptic medication and bone health |
| Q46313804 | Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy |
| Q91583668 | Bone Mineral Density Loss in People With Epilepsy Taking Valproate as a Monotherapy: A Systematic Review and Meta-Analysis |
| Q91601720 | Bone health in pediatric patients with neurological disorders |
| Q37702229 | Bone loss associated with use of antiepileptic drugs |
| Q51059654 | Bone mineral density in ambulatory children with epilepsy. |
| Q33997446 | Bone status in patients with epilepsy: relationship to markers of bone remodeling |
| Q51399526 | BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. |
| Q36257188 | Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder |
| Q35433533 | Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF. |
| Q37186130 | Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy? |
| Q35238351 | Effects of long-term combination treatment with valproate and atypical antipsychotics on bone mineral density and bone metabolism in premenopausal patients with bipolar disorder: a preliminary study |
| Q26741198 | Epigenetic Mechanisms in Bone Biology and Osteoporosis: Can They Drive Therapeutic Choices? |
| Q56604475 | Evaluation of bone health among epileptic patients using biochemical markers and DEXA scan: an Egyptian study |
| Q39932979 | HDAC2 regulates FoxO1 during RANKL-induced osteoclastogenesis |
| Q35555670 | HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling |
| Q35556841 | Hdac-mediated control of endochondral and intramembranous ossification |
| Q36146330 | Histone Deacetylases in Bone Development and Skeletal Disorders. |
| Q38893201 | Histone Deacetylases in Cartilage Homeostasis and Osteoarthritis |
| Q34475885 | Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells |
| Q38429655 | Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. |
| Q34612849 | Histone deacetylases in skeletal development and bone mass maintenance |
| Q28074005 | Impact of antiepileptic drugs on bone health: Need for monitoring, treatment, and prevention strategies |
| Q35030533 | In Vitro and In Vivo Osteogenic Activity of Largazole. |
| Q37842459 | Influences of bone and mineral metabolism in epilepsy. |
| Q58617588 | Integrative regulation of physiology by histone deacetylase 3 |
| Q36622128 | Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management |
| Q38640619 | Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs. |
| Q37335897 | Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome. |
| Q35924416 | Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics-a Review. |
| Q28475498 | Phase II open label study of valproic acid in spinal muscular atrophy |
| Q51143850 | Phenytoin and sodium valproate but not levetiracetam induce bone alterations in female mice. |
| Q36007883 | Potential effects of valproate and oxcarbazepine on growth velocity and bone metabolism in epileptic children- a medical center experience |
| Q38993135 | Profiling of human epigenetic regulators using a semi-automated real-time qPCR platform validated by next generation sequencing |
| Q64069924 | Regulation of Osteoclast Differentiation and Skeletal Maintenance by Histone Deacetylases |
| Q39030320 | Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd |
| Q34810920 | Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. |
| Q86999078 | Survey of risk factors for osteoporosis and osteoprotective behaviors among patients with epilepsy |
| Q37161345 | The association of newer anticonvulsant medications and bone mineral density |
| Q38211406 | The problem of osteoporosis in epileptic patients taking antiepileptic drugs. |
| Q36717858 | Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis |
Search more.